Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423643 · ClinicalTrials.gov registry record
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 1,250
- Enrollment target
NCT01423643: Completed study, sponsored by Johns Hopkins University.
NCT01423643 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 1,250 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01423643 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 1,250 participants
- Enrollment target
Study Summary
The chief purpose of this research is to understand how antiretroviral therapy (ART) affects progression of liver disease in persons co-infected with HIV and hepatitis C virus (HCV). The investigators study liver disease progression in a cohort of dually infected persons according to the success of ART.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2001-03 |
| Est. Completion | 2015-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01423643
The ClinicalTrials.gov registry entry for NCT01423643 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01423643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01423643 about?
NCT01423643 is a clinical study titled "HCV/HIV Coinfection: Antiviral Therapy and Fibrosis". The chief purpose of this research is to understand how antiretroviral therapy (ART) affects progression of liver disease in persons co-infected with HIV and hepatitis C virus (HCV). The investigators study liver disease progression in a cohort of dually infected persons according to the success of ...
What is the current status of trial NCT01423643?
This trial is currently completed. The enrollment target is 1,250 participants. The study started on 2001-03. Estimated completion is 2015-10.
Who is sponsoring clinical trial NCT01423643?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.